Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. saw a notable increase in its stock performance on March 24, 2026, reaching an intraday high. Despite a year-to-date decline, the company has outperformed the broader market over the past year, operating within the mid-cap pharmaceuticals sector with a significant market capitalization.

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. faced a notable decline in its stock price, contrasting with broader market trends. The company reported a significant drop in net sales and pre-tax profit in the latest quarter, while its annual return remains positive despite recent challenges in performance metrics.

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. faced a notable decline in its stock today, contrasting with the broader market's performance. The company has struggled with profitability, evidenced by a significant drop in pre-tax profit, and has experienced a substantial decrease in stock value over the past three years.

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. saw a significant rise on March 16, 2026, contrasting with a decline in the China Shanghai Composite index. Despite a solid weekly gain and strong annual performance, the company faces challenges with a recent net sales decline and high valuation metrics.

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. saw a significant intraday increase on March 5, 2026, contrasting with a decline in the broader market. Despite recent challenges, the company has shown strong annual performance, with a notable market capitalization and key financial metrics reflecting its position in the pharmaceuticals sector.

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. faced a notable decline in its stock today, contrasting with the broader market. The company has experienced significant downturns over the past week and month, alongside challenges in profitability, including a sharp drop in net sales and pre-tax profit.